Literature DB >> 9568165

Glucosylceramide: a marker for multiple-drug resistant cancers.

A Lucci1, W I Cho, T Y Han, A E Giuliano, D L Morton, M C Cabot.   

Abstract

BACKGROUND: Multiple-drug resistance (MDR) is a major reason for chemotherapy failure. Herein we describe glucosylceramide, a new marker for MDR.
METHODS: Cellular lipids were analyzed in three human MDR cancer cell lines and their drug-sensitive counterparts. Analysis of glucosylceramide was also performed in six melanoma specimens and one breast tumor specimen obtained from patients who had undergone chemotherapy. Glucosylceramide, analyzed by mass and by cellular utilization of radiolabeled precursor ([3Hpalmitic acid), was isolated by lipid extraction techniques and resolved from other components by thin-layer chromatography.
RESULTS: Glucosylceramide was present consistently in all MDR cell lines and was absent, or present only at very low levels, in the corresponding drug-sensitive cells. Examination of human tumor specimens documented presence of the marker in all patients who had failed chemotherapy, and absence of the marker in each of the patients with known clinical response to chemotherapy. The response to chemotherapy was followed for a median of 8 months in melanoma patients and for 22 months in the breast cancer patient.
CONCLUSION: These findings suggest that glucosylceramide may hold clinical significance for the early identification of drug-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9568165

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  42 in total

1.  Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.

Authors:  Yusuf Baran; Jacek Bielawski; Ufuk Gunduz; Besim Ogretmen
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-11       Impact factor: 4.553

2.  Glucosylceramide synthesis inhibition affects cell cycle progression, membrane trafficking, and stage differentiation in Giardia lamblia.

Authors:  Sasa Stefanić; Cornelia Spycher; Laura Morf; Gemma Fabriàs; Josefina Casas; Elisabeth Schraner; Peter Wild; Adrian B Hehl; Sabrina Sonda
Journal:  J Lipid Res       Date:  2010-03-24       Impact factor: 5.922

Review 3.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

Review 4.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

Review 5.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 6.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

7.  Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Ping Xie; Xin Gu; Armando E Giuliano; Myles C Cabot
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

8.  Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.

Authors:  Jacqueline V Chapman; Valérie Gouazé-Andersson; Maria C Messner; Margaret Flowers; Ramin Karimi; Mark Kester; Brian M Barth; Xin Liu; Yong-Yu Liu; Armando E Giuliano; Myles C Cabot
Journal:  Biochem Pharmacol       Date:  2010-04-10       Impact factor: 5.858

9.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

10.  A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Authors:  Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.